ArticleACS omega2025
Development and Characterization of Zein/Eudragit Composite Nanoparticles for Insulin Intranasal Delivery.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual drug co-encapsulation into liposomes and liposome-derived nanosystems for improved synergistic treatment of skin diseases.Drug delivery and translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated blood glucose levels, primarily due to impaired insulin secretion or action. The standard treatment for Type 1 Diabetes Mellitus still involves daily parenteral insulin administration, which presents several challenges including patient discomfort, reduced adherence, and the potential for peripheral hyperinsulinemia. Intranasal administration has emerged as a promising alternative due to the nasal cavity's high vascularization, ease of access, and significant absorption capacity, though certain physiological barriers remain. This study aimed to develop and characterize Zein-Eudragit nanoparticles (NPS) as carriers for insulin (ZEU/INS NPS) intended for intranasal administration. The NPS were prepared using a liquid-liquid dispersion method, and the production process was optimized through a 2
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.